148 related articles for article (PubMed ID: 9484672)
1. Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.
Morris DL; Dillon PW; Very DL; Ng P; Kish L; Goldblatt JL; Bruzek DJ; Chan DW; Ahmed MS; Witek D; Fritsche HA; Smith C; Schwartz D; Schwartz MK; Noteboom JL; Vessella RL; Yeung KK; Allard WJ
J Clin Lab Anal; 1998; 12(1):65-74. PubMed ID: 9484672
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen.
Vessella RL; Noteboom J; Lange PH
Clin Chem; 1992 Oct; 38(10):2044-54. PubMed ID: 1382897
[TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay.
Allard WJ; Cheli CD; Morris DL; Goldblatt J; Pierre Y; Kish L; Chen Y; Dai J; Vessella RL; Chan DW; Schwartz MK; Zhou Z; Yeung KK
Int J Biol Markers; 1999; 14(2):73-83. PubMed ID: 10399626
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)--multi-centre study results. The PSA Study Group.
Schambeck CM
Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):541-7. PubMed ID: 8547440
[TBL] [Abstract][Full Text] [Related]
5. Abbott IMx evaluated for assay of prostate-specific antigen in serum.
Dnistrian AM; Schwartz MK; Smith CA; Nisselbaum JS; Fair WR
Clin Chem; 1992 Oct; 38(10):2140-2. PubMed ID: 1382898
[TBL] [Abstract][Full Text] [Related]
6. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
10. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
Black MH; Magklara A; Obiezu CV; Melegos DN; Diamandis EP
Clin Chem; 1999 Jun; 45(6 Pt 1):790-9. PubMed ID: 10351987
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an automated chemiluminescent immunoassay for complexed PSA on the Bayer ACS:180 system.
Datta P; Dasgupta A
J Clin Lab Anal; 2003; 17(5):174-8. PubMed ID: 12938146
[TBL] [Abstract][Full Text] [Related]
12. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
14. Performance evaluation of a new chemiluminescent assay for prostate specific antigen.
Dasgupta A; Wells A; Datta P
J Clin Lab Anal; 2000; 14(4):164-8. PubMed ID: 10906769
[TBL] [Abstract][Full Text] [Related]
15. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer.
Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
Clin Chem Lab Med; 2003 Jan; 41(1):90-4. PubMed ID: 12636056
[TBL] [Abstract][Full Text] [Related]
16. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
17. Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer.
Tello FL; Prats CH; González MD
Clin Chem Lab Med; 2001 Feb; 39(2):116-20. PubMed ID: 11341744
[TBL] [Abstract][Full Text] [Related]
18. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Onur R; Ilhan N; Orhan I; Ilhan N
World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
